TY - JOUR
TI - Weak stromal Caveolin-1 expression in colorectal liver metastases
predicts poor prognosis after hepatectomy for liver-only colorectal
metastases
AU - Neofytou, Kyriakos
AU - Pikoulis, Emmanouil
AU - Petrou, Athanasios and
AU - Agrogiannis, Georgios
AU - Petrides, Christos
AU - Papakonstandinou,
AU - Ioannis
AU - Papalambros, Alexandros
AU - Aggelou, Anastasios and
AU - Kavatzas, Nikolaos
AU - Liakakos, Theodoros
AU - Felekouras, Evangelos
JO - Scientific Reports
PY - 2017
VL - 7
TODO - null
SP - null
PB - Nature Publishing Group
SN - 2045-2322
TODO - 10.1038/s41598-017-02251-9
TODO - null
TODO - Loss of stromal Caveolin-1 (CAV1) expression is associated with poor
prognosis in various cancers. We evaluated the prognostic value of CAV1
expression of both cancer cells and stromal cells in colorectal liver
metastases (CRLM) in patients undergoing hepatectomy. In this
retrospective study, 109 patients were enrolled. CAV1 expression was
studied by immunohistochemistry. The staining was scored
semiquantitatively as weak or strong. Disease-free survival (DFS) and
overall survival (OS) were calculated using both Kaplan-Meier and
multivariate Coxregression methods. Weak stromal CAV1 expression was
associated with decreased DFS and OS in univariate and in multivariate
analysis (HR 2.00; 95% CI, 1.24-3.22; P = 0.004, and HR 2.47; 95% CI,
1.28-4.76; P = 0.007, respectively). Cancer cell CAV1 expression was not
associated with DFS and OS. Five-year DFS and OS rates were 13% and
43%, respectively, in patients with weak stromal CAV1 expression and
40% and 71%, respectively, in patients with strong stromal CAV1
expression. In this study, we indicate that weak stromal CAV1 expression
in CRLM is an adverse prognostic factor in patients who undergo liver
resection for liver-only colorectal metastases. We suggest validation of
this finding in an independent cohort and consideration of risk
stratification for post-hepatectomy adjuvant follow-up and therapy.
ER -